Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KRAS
Biotech
GSK pens $1.3B Hutchmed deal for KRAS-EGFR cancer asset
GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology asset.
Ben Adams
Sep 3, 2026 7:45am
Fierce Pharma
FDA greenlights RevMed’s pancreatic cancer gamechanger
Aug 26, 2026 11:30am
BlossomHill eyes IPO to grow taller in crowded cancer fields
Jul 17, 2026 12:08pm
Roche orchestrates phase 3 lung cancer win over Amgen and BMS
Jul 2, 2026 8:30am
J&J makes $1B bet on emerging DAC space by netting Firefly Bio
Jun 8, 2026 10:05am
ASCO: RevMed confident in RAS leadership as rivals square up
May 31, 2026 8:00am
Fierce Pharma
Fierce Pharma
Fierce Pharma
Fierce Pharma
